Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells. In patients with cystic fibrosis, high concentrations of extracellular DNA are commonly found in the sputum as a result of the body’s innate response to respiratory infections. This increases the viscoelasticity of the mucus, reducing pulmonary function and increasing risk of further infection. Pulmozyme hydrolyzes DNA, reducing the viscoelasticity of sputum and encouraging its clearance.
LIST OF FIGURES
9 Figure 1: Pulmozyme for cystic fibrosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Pulmozyme for cystic fibrosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Pulmozyme for cystic fibrosis
13 Figure 4: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
5 Table 1: Pulmozyme drug profile
7 Table 2: Pulmozyme pivotal trial data in cystic fibrosis
14 Table 3: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.